TrialBritish journal of haematology2021

Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Animesh Pardanani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.